Latest Conference Articles

Dr. Danuser Discusses Impact of RacP29S Mutation in Melanoma

Gaudenz Danuser, PhD, discusses how the activation of RacP29S impacts the treatment of patients with melanoma. His lab has been studying the Rac molecule for around 20 years. The RacP29S mutation most commonly appears in melanoma, but it has since been discovered in a few other cancer types as well.

Combination BRAF/MEK Inhibition Induces Potent Antitumor Activity in NRAS+ Melanoma

Combining a BRAF inhibitor with a MEK inhibitor causes endoplasmic reticulum stress in BRAF wild-type, NRAS­-mutated melanoma cells, resulting in significant antitumor activity.

Dr. Penson on Treatment Selection in Metastatic Hormone-Sensitive Prostate Cancer

David F. Penson, MD, MPH, MMHC, discusses treatment selection in patients with metastatic hormone-sensitive prostate cancer.

Dr. Warner Discusses Findings from COMBI-i Trial in Melanoma

Allison Betof Warner, MD, PhD, discusses the excitement surrounding the findings from the COMBI-i trial that was presented at the 2019 ASCO Annual Meeting. This trial investigated the combination of PD-1 inhibitor spartalizumab with dabrafenib plus trametinib in patients with advanced BRAF V6000mutant melanoma.

Dr. Shoushtari on the Data from the First-in-Human Trial for Tebentafusp in Advanced Melanoma

Alexander N. Shoushtari, MD, discusses the significance of the findings from the first-in-human trial evaluating tebentafusp, a TCR–CD3 bispecific, in patients with advanced melanoma.

Dr. Chang on the Use of PARP Inhibitors in Prostate Cancer

Sam S. Chang, MD, MBA, discusses the shift toward personalized therapy in prostate cancer.

Selecting Among AR-Directed Agents in Nonmetastatic CRPC

David Morris, MD, FACS, provides an update on the 3 newest agents available for nonmetastatic castration-resistant prostate cancer treatment and discussed factors to consider when choosing among them.

Dr. Owonikoko on Standard of Care for SCLC

Taofeek K. Owonikoko, MD, PhD, discusses current standard of care treatments for patients with small cell lung cancer.

Dr. Kelly on Determining Second-Line TKI in Lung Cancer

Karen Kelly, MD, discusses how to determine treatment after patients with lung cancer progress on TKIs.

NGS Testing Is Essential Before Induction in NSCLC

Suresh S. Ramalingam, MD, FASCO, highlights current and emerging therapies for 6 key actionable driver mutations in non–small cell lung cancer.

Dr. Borghaei on the Search for Biomarkers in Lung Cancer

Hossein Borghaei, DO, MS, discusses the search for biomarkers in lung cancer.

Dr. Halmos on Actionable Biomarkers in NSCLC

Balazs Halmos, MD, MS, discusses actionable biomarkers in patients with oncogene-driven non–small cell lung cancer.

Dr. Hirsch on the Expansion of Molecular Testing in Lung Cancer

Fred R. Hirsch, MD, PhD, discusses the expansion of molecular testing in lung cancer.

Plasma NGS Demonstrating Practice-Changing Potential in NSCLC

Plasma genotyping is the next big thing in non–small cell lung cancer, and it's already impacting clinical practice.

Osimertinib Positioned as Preferred Frontline Treatment for EGFR-Mutant NSCLC

Zofia Piotrowska, MD, MHS, discusses the role of osimertinib in treating patients with EGFR-mutant non–small cell lung cancer and how it compares with other therapeutic options in that space.

Dr. Ramalingam on FLAURA Trial Results in EGFR-Mutant NSCLC

Suresh S. Ramalingam, MD, FASCO, discusses updated data from the FLAURA trial in EGFR-mutant non–small cell lung cancer.

Dr. Hanna on Challenges With Consolidation Immunotherapy in Lung Cancer

Nasser H. Hanna, MD, discusses challenges in consolation immunotherapy for patients with lung cancer.

Role of Neoadjuvant Immunotherapy Being Refined in Resectable NSCLC

Neoadjuvant immunotherapy can offer promise to patients with resectable non–small cell lung cancer, but further investigation is required for optimal use, Tina Cascone, MD, PhD, said in a presentation during the 14th Annual New York Lung Cancers Symposium®.

Neoadjuvant Approaches Showcase Advantages in NSCLC

Based on efficacy, tolerability, and practicality, neoadjuvant therapy in lung cancer offers significant advantages over adjuvant treatment, said Jamie E. Chaft, MD, in a presentation during the 14th Annual New York Lung Cancers Symposium®. However, she added, adjuvant treatment predominantly remains the standard of care at many cancer centers, she said.

Levy Lends Insight on Evolving Treatment Strategies in Lung Cancer

Benjamin P. Levy, MD, discusses therapeutic strategies for patients with oncogenic-driven and nondriver non–small cell lung cancer.

Moxetumomab Pasudotox Poised to Answer Ongoing Questions in Hairy Cell Leukemia

Robert J. Kreitman, MD, discusses the role of minimal residual disease (MRD) status in hairy cell leukemia, how to effectively test for MRD, and how the combination of moxetumomab pasudotox and rituximab could alter the treatment landscape.

Can Combo of Vemurafenib and Obinutuzumab Shake Up Hairy Cell Leukemia Paradigm?

The standard of care for the frontline treatment of patients with hairy cell leukemia has been purine nucleoside analogs, including pentostatin and cladribine; however, investigators are challenging this treatment in a phase II clinical trial with a targeted therapy that may provide similar benefit with fewer toxicities.

Vemurafenib Induces Deep, Durable Remissions in Heavily Pretreated Hairy Cell Leukemia

Agnieszka Janus, MD, PhD, shares perspective on three cases of patients with HCL who were given vemurafenib after having progressed on multiple lines of treatment.

Ongoing Trial Demonstrates Promising PFS With Ibrutinib in Hairy Cell Leukemia

Kerry Rogers, MD, discusses the potential of ibrutinib (Imbruvica) in hairy cell leukemia, emerging treatment options such as moxetumomab pasudotox (Lumoxiti), and next steps and challenges in the field.

Dr. Kreitman on MRD-Negative CRs With Moxetumomab Pasudotox in Hairy Cell Leukemia

Robert J. Kreitman, MD, discusses the association between minimal residual disease-negativity and complete remission durations in patients with hairy cell leukemia treated with moxetumomab pasudotox.

Dr. Taylor on Ongoing Phase II Trial of Frontline Vemurafenib Combo in Hairy Cell Leukemia

Justin Taylor, MD, discusses the design of an ongoing phase II clinical trial evaluating the combination of frontline vemurafenib plus obinutuzumab in patients with hairy cell leukemia.

Dr. Blachly on ctDNA as a Biomarker in Hairy Cell Leukemia

James Blachly, MD, discusses the role of circulating tumor DNA as a biomarker for patients with hairy cell leukemia.

Dr. Rogers on Data for Ibrutinib in Hairy Cell Leukemia

Kerry Rogers, MD, discusses the results from an ongoing phase II trial investigating ibrutinib in patients with relapsed/refractory hairy cell leukemia. Because this represents a very rare patient population, accrual began in 2013, and these data reflect on a small portion of the 39 patients enrolled.

Dr. Tiacci on Standard of Care in Hairy Cell Leukemia Treatment

Enrico Tiacci, MD, discusses the current treatment options for patients with hairy cell leukemia. Currently, the standard of care for these patients are purine nucleoside analogs, including pentostatin and cladribine.

Dr. Janus on the Role of Moxetumomab Pasudotox in Hairy Cell Leukemia

Agnieszka Janus, MD, PhD, discusses the efficacy and safety of moxetumomab pasudotox as a treatment option for patients with hairy cell leukemia. This agent was approved by the FDA in September 2018 for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy, including a purine nucleoside analog.